Article Text

Download PDFPDF

Physicians’ real-world experience with IDegLira: results of a European survey
  1. Russell Drummond1,
  2. Ankita Baru2,
  3. Marcelina Dutkiewicz3,
  4. Amaury Basse3,
  5. Bengt-Olov Tengmark4
  1. 1 Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK
  2. 2 IQVIA, Rotkreuz, Switzerland
  3. 3 Novo Nordisk A/S, Søborg, Denmark
  4. 4 Citydiabetes, Stockholm, Sweden
  1. Correspondence to Dr Russell Drummond; russell.drummond{at}glasgow.ac.uk

Abstract

Objective This study aimed to build on the current clinical findings and investigate physicians’ experiences and level of satisfaction in using insulin degludec/liraglutide (IDegLira) to treat patients with type 2 diabetes (T2D).

Research design and methods This multicountry, European online survey included respondents from primary (n=132) and secondary (n=103) care and examined physicians’ use, confidence and satisfaction with IDegLira. To standardize responses, 24 of 28 questions pertained to an ‘average patient’ with T2D who has no major comorbidities, aged 35–70 years, with average cognitive ability/normal mental status and body mass index ≥25 kg/m2.

Results The majority (70%) of respondents prescribe IDegLira in the same visit they first mention it, with uncontrolled glycated hemoglobin (HbA1c) (44%) and weight gain (22%) being the most common reasons. On average, physicians reported that patients weighed 95 kg and the HbA1c level was 9.0% at initiation. Physicians also reported the average HbA1c target set was 7.1%; 76% of patients achieved their target. On average, patients achieved their HbA1c target in <6 months, and the average dose of IDegLira in patients in glycemic control was 28 dose steps. Respondents were more satisfied with IDegLira than basal-bolus therapy across all parameters assessed, including reaching HbA1c targets (59%), number of injections (77%) and avoiding weight gain (84%). Correspondingly, 77% of physicians reported that IDegLira had more potential to improve patient motivation compared with basal-bolus to reach target blood glucose levels.

Conclusions Real-world experience of IDegLira is consistent with previous trials/studies, with no major differences between primary and secondary care. Importantly, the majority of respondents were more/much more satisfied with IDegLira than with basal-bolus therapy.

  • Observational study
  • basal
  • insulin treatment in type
  • addTrackChanges">2 diabetes
  • GLP-1

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors AmB and MD contributed to the design, analysis and manuscript writing. AnB contributed to the conduct/data collection, analysis and manuscript writing. RD and B-OT contributed to the analysis and manuscript writing. The authors take full responsibility for the final content and the decision to submit the article for publication.

  • Funding The survey and the manuscript were sponsored by Novo Nordisk. The survey was conducted by QuintilesIMS, and medical writing assistance and submission support were provided by Victoria Atess and Germanicus Hansa-Wilkinson of Watermeadow Medical, an Ashfield company, part of UDG Healthcare, funded by Novo Nordisk.

  • Competing interests RD has received speaker fees, fees for advisory service and support to attend educational meetings from Novo Nordisk, Sanofi, Takeda, AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Merck, Sharp & Dohme. AnB has no conflicts of interest to declare. AmB and MD are employees of Novo Nordisk. B-OT has received speaker fees, fees for advisory service and support to attend educational meetings from Novo Nordisk, Sanofi, AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Merck, Sharp & Dohme.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement This material has not been published previously and is not under consideration for publication elsewhere.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles